Patients with moderate to severe chronic obstructive pulmonary disease (COPD) can benefit from triple therapy that includes a long-acting beta-agonist, an inhaled corticosteroid and an anti-muscarinic agent, according to researchers.
Patients with moderate to severe chronic obstructive pulmonary disease (COPD) can benefit from triple therapy that includes a long-acting beta-agonist, an inhaled corticosteroid and an anti-muscarinic agent, according to researchers.